TargetMol

Uridine-5'-diphosphate disodium salt

Product Code:
 
TAR-T4706
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T4706-50mg50mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4706-100mg100mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4706-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4706-500mg500mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
UDP is a specific agonist of the P2Y6 receptors (EC50 = 13 nM for human P2Y6), stimulating the production of inflammatory mediators, phagocytosis, and vasoconstriction. UDP also acts as an antagonist of P2Y14.
CAS:
27821-45-0
Formula:
C9H14N2Na2O12P2
Molecular Weight:
450.14
Pathway:
GPCR/G Protein; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism; Neuroscience
Purity:
0.986
SMILES:
O[C@H]1[C@H](N2C(NC(C=C2)=O)=O)O[C@@H]([C@H]1O)COP(OP(O)(O)=O)(O)=O.[Na].[Na]
Target:
DNA/RNA Synthesis; Endogenous Metabolite; P2Y Receptor

References

Jacobson, K.A., et al. Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 5(1), 75-89 (2009). Abbracchio, M.P., et al. International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacological Reviews 58(3), 281-341 (2006).